CORAL GABLES, FL / ACCESSWIRE / March 27, 2019 / The future of the healthcare stock market is directly correlated to whether companies in the healthcare sector have what it takes to meet the growing health challenges facing society. According to recent statistics, global shortages in primary care physicians coupled with rising populations has left millions without access to acute care. Luckily, there are healthcare companies rising to the challenge with innovative medical technologies and nuanced approaches to how we treat and care for our patients. Though we're only a few months into 2019, this year could be promising for the healthcare sector. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Seelos Therapeutics Inc (SEEL), Novavax Inc (NVAX), and Trillium Therapeutics Inc (TRIL) are 4 healthcare companies heating things up on Wednesday.
Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company determined to develop innovative approaches that combine human skill-based expertise with state-of-the-art technologies to offer to their patients the best possible treatment solutions and primary care. At a time where consumers depend on healthcare companies to provide quality care solutions, Premier Health is prepared to meet the needs of its patients.
Premier Health Group (OTC:PHGRF) (CSE:PHGI) today announced the Company has initiated integration of CB2 Insights' medical cannabis Clinical Decision Support tool. Per the details of the initiative, the agreement will give the more than 4600 physicians and healthcare practitioners using Premier Health's Juno EMR platform access to the industry's only medical cannabis-specific CDS tool. CB2 Insights' CDS tool is designed to help incorporate medical cannabis into their patient's treatment plans.
Following the announcement, Dr. Essam Hamza, CEO of Premier Health Group (OTC:PHGRF) (CSE:PHGI), stated, "we are dedicated to finding new ways to create value for our physician network. We continue to receive multiple requests from physicians who ask about how best to incorporate medical cannabis into their clinics. This agreement with CB2 will provide us a robust, validated tool to give our physicians and healthcare practitioners a safe and secure way to qualify, educate and where appropriate, prescribe medical cannabis to their patients in a compliant manner."
Seelos Therapeutics Inc (SEEL), a clinical-stage biopharmaceutical company, earlier this month announced that the Company had acquired an exclusive license to intellectual property owned by The Regents of the University of California pertaining to a technology that was created by researchers at the University of California, Los Angeles. Per the details of the announcement, such technology relates to a family of rationally-designed peptide inhibitors that target the aggregation of alpha-synuclein (α-synuclein).
Raj Mehra, Founder, and CEO of Seelos said, "accumulation and aggregation of α-synuclein is a pathological hallmark of PD. Though its role is not completely understood, it appears pivotal in the pathogenesis of PD and other α-synucleinopathies such as dementia with Lewy bodies and multiple system atrophy."
Novavax Inc (NVAX) this month shared its financial results and operational highlights for the fourth quarter and twelve months ended December 31, 2018. Per the results, in February, Novavax announced top-line data from the Prepare trial, which was initiated in December 2015 to determine the efficacy of ResVax against medically significant RSV-positive lower respiratory tract infection in infants.
Stanley C. Erck, President, and CEO of Novavax said, "in 2018, we committed to focus on our two lead programs, ResVax™, and Nanoflu™ and reflecting on last year's activities, I am proud to say we have achieved significant results for both. Although we were disappointed to miss the primary endpoint of our Prepare trial, ResVax is the first RSV vaccine to demonstrate efficacy for the prevention of RSV disease in Phase 3 clinical trial. In addition, the successful Phase 2 results for our NanoFlu vaccine provide an opportunity to now confirm with the FDA the use of accelerated approval for licensure."
Trillium Therapeutics Inc (TRIL), a clinical-stage immune-oncology company developing innovative therapies for the treatment of cancer, earlier this month reported financial and operating results for the year ended December 31, 2018. Over the course of the last year, the Company initiated a multicenter, open-label, phase 1a/1b study of TTI-622 (SRIPaFc-IgG4) in patients with advanced relapsed or refractory lymphoma or multiple myeloma. In the phase 1a dose-escalation part, patients are enrolled in sequential dose cohorts to receive TTI-622 once weekly to characterize the safety, tolerability, pharmacokinetics, and to determine the maximum tolerated dose.
Niclas Stiernholm, President and CEO of Trillium, commented, "In 2018 we presented clear evidence of single-agent activity in B- and T-cell lymphoma. We believe that TTI-621 is the most potent CD47-blocking agent in the clinic due to its IgG1 Fc region, which can deliver an activating signal to the immune system. What is especially noteworthy is the ability of TTI-621 to stimulate a rapid anti-tumor response when administered intratumorally to patients with cutaneous T-cell lymphoma. We are also encouraged by the activity we have seen after intravenous delivery of relatively low doses, and look forward to characterizing the responses as we continue to dose intensify."
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.
Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. Midam was hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 ( CASH) for & were paid "500,000" shares of restricted common shares (as of 1/2/2019). Midam has been compensated an additional $100,000 by Premier Health Group to extend the period of coverage to June 1, 2019. As of 3/26/2019 Midam has been compensated an additional $100,000 by Premier Health Group for additional coverage without further extended coverage duration. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.
View source version on accesswire.com: